Focus on metformin - A major cardiovascular medication: 'Diabesity - The biggest epidemic in human history'

Cardiovascular Journal of Africa

Volumn 18, Issue 5, 2007, Pages 331-333

  Straughan, John L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUFORMIN; GALEGA OFFICIANALIS EXTRACT; GLITAZONE DERIVATIVE; METFORMIN; PHENFORMIN; PLANT EXTRACT; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

AGITATION; ANOREXIA; BLOATING; BODY MASS; BODY WEIGHT; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG HALF LIFE; FLATULENCE; FOOD DRUG INTERACTION; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; INDIGESTION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LACTIC ACIDOSIS; LOW DRUG DOSE; MALAISE; MUSCLE CRAMP; NAUSEA; NEUROLOGIC DISEASE; SHORT SURVEY; SIDE EFFECT; TASTE DISORDER; VOMITING;

BLOOD GLUCOSE; BODY WEIGHT; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DISEASE OUTBREAKS; ENDOTHELIUM, VASCULAR; EXERCISE; HEMODYNAMICS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPID METABOLISM; METFORMIN; OBESITY;

EID: 40949151074     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (37)

1. Zimmet P. Diabesity - the biggest epidemic in human history. Medscape Gen Med 2007; 9: 39.
2. Wood S. Early glimpse at findings of study: RISC (Relatioship Between Insulin Sensitivity and Cardiovascular Risk) underscores physical activity benefits and suggests insulin sensitivity is not a 'sole driver' of risk. European Association for the Study of Diabetes (EASD) meeting, Amsterdam, press release. Sept 19, 2007.
3. Witters LA. The blooming of the French lilac. J Clin Invest 2001; 108: 1105-1107.
4. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; 1: art no CD002967.
5. Turner MJ, Walsh J, Byrne KM, et al. Outcome of clinical pregnancies after ovulation induction using metformin. J Obstet Gynaecol 2006; 26: 233-235.
6. Glueck CJ, Wang P. Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert Opin Drug Safety 2007; 6: 191-198.
7. Mokdad AH, Mark JS, Stroup JS, Gerberding JL. Actual causes of death in the United States. J Am Med Assoc 2004; 291: 1238-1245.
8. Lindstrom J, Louheranta A, Mannelin M, et al. The Finnish Diabetes Prevention Study: life style intervention and 3-year results on diet and physical exercise. Diabetes Care 2003; 26: 3230-3236.
9. Golay A. Metformin and body weight. Int J Obes 2007; July: 1-12.
10. Nagi DK, Mohamed A, Yudkin JS. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus. Diabet Med 1996; 13: 753-757.
11. Lachin JM, Costas CA, Edelstein SL, et al. Factors associated with diabetes onset during metformin versus placebo therapy in the Diabetes Prevention Program. Diabetes 2007; 56: 1153-1159.
12. Srinivasan S, Ambler GR, Baur LA, et al. Randomised controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvements in body composition and fasting insulin. J Clin Endocrinol Metab 2006; 10: 2074-2080.
13. English PJ, Ashcroft A, Patterson M, et al. Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes. Diabetes Metab Res Rev 2007; 23: 299-303.
14. Lund SS, Tarnow L, Stehouwer CD, et al. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes Obes Metab 2007; 9: 394-407.
15. Gerstein HC, Pogue J, Mann JF, et al. HOPE investigators. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005; 48: 1749-1755.
16. Rudge JB, Assendelft WJ, Dekker JM, et al. Insulin and the risk of cardiovascular disease: a meta-analysis. Circulation 1998; 97: 996-1001.
17. Stumvoll M, Nurjahan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554.
18. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 102: 491-497.
19. De Fronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-549.
20. Bailey C, Turner R. Metformin. N Engl J Med 1996; 334: 574-579.
21. Monnier L, Collete C, Thuan J-F, Lapinski H. Insulin secretion and sensitivity of HbA1c in type 2 diabetes. Eur J Clin Invest 2006; 36: 231-235.
22. Patane G, Piro S, Rabuazzo AM, et al. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct effect on pancreatic beta-cells. Diabetes 2000; 49: 735-740.
23. Khan AS, McLoughney CR, Ahmed AB. The effect of metformin on blood glucose control in overweight patients with type 1 diabetes. Diabet Med 2006; 23: 1079-1084.
24. Moon RJ, Bascombe LA, Holt RI. The addition of metformin in type 1 diabets improves insulin sensitivity, diabetic control, body composition and patient well-being. Diabetes Obes Metab 2007; 9: 143-145.
25. Mourao CA (jun), Sa JR, Guedes OM, Dib SA. Effect of metformin on the glycemic control, lipid profile and arterial pressure of type 2 diabetic patients with metabolic syndrome already on insulin. Braz J Med Res 2006; 39: 489-494.
26. Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution: BIGPRO Study Group. Diabetes Care 1996; 19: 920-926.
27. Lawrence JM, Reid J, Taylor GJ, et al. Favourable effects of pioglitazome and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004; 27: 41-46.
28. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al. Insulin sensitizers in treatment of non-alcoholic fatty liver disease: systematic review. Wld J Gastoenterol 2006; 12: 7826-7831.
29. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-894.
30. Bugianesi E, Gentilcore E, Manini R, Natale S, et al. A rendomized trial of metformin versus vitamin E or prescriptive diet in non-alcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082-1090.
31. Cersosimo E, DeFromzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular disease. Diabetes Metab Res Rev 2006; 22: 324-436.
32. Hoffmann IS, Alfieri AB, Cubeddu LX. Effects of lifestyle changes and metformin on salt sensitivity and nitric oxide metabolism in obese salt-sensitive Hispanics. J Hum Hypertens 2007; 21: 571-578.
33. Caballero AE, Delgado A, Aguilar-salinas CA, et al. The differential effects of metformin on markers of endothelial function and inflammation in subjects with impaired glucose tolerance: A placebo-controlled randomised clinical trial. J Clin Endocrinol Metab 2004; 89: 3943-3948.
34. Klein S Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease. Circulation 2004; 110: 2952-2967.
35. De Jager J, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomised placebo-controlled trial. J Intern Med 2005; 257: 100-109.
36. Mather KJ, Verma S, Anderson TJ, et al. Improved endothelial function with metformin and type 2 daibets mellitus. J Am Coll Cardiol 2001; 37: 1344-1350.
37. Roberts F, Ryan GJ. The safety of metformin in heart failure. Ann Pharmacother 2007; 41: 642-646.